NephroPlus files FY26 Annual Report; revenue rises 32%, adjusted PAT up 75%

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF

NEPHROPLUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.3%1-day move

₹639.00

prior close

₹632.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.1-0.3-0.3-0.3-1.3-1.9+5.5+5.8+5.8+8.3————

Up moveDown movePending

AI summary

NephroPlus filed its 17th Annual Report for FY26 following its December 2025 listing on BSE and NSE. Revenue from operations grew 32.2% to Rs 998.8 crore. EBITDA rose 36.2% to Rs 227 crore with margin expanding 70 basis points to 22.7%. Adjusted PAT surged 74.6% to Rs 128.3 crore. The company serves 36,981 guests across 520 plus clinics in five countries, with international revenue contributing about 42%.

Likely market impact

Strong revenue growth and margin expansion reinforce growth story; sharp 75% adjusted PAT jump signals profitability scaling after listing.